The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation

(2020) Huaxia Yang et al.   CLINICAL IMMUNOLOGY

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

(2020) Elizaveta Efuni et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

(2020) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

(2020) Mitchell S von Itzstein et al.   CLINICAL CHEMISTRY

Moving towards personalized treatments of immune-related adverse events

(2020) Khashayar Esfahani et al.   Nature Reviews Clinical Oncology

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

(2020) Nieves Martinez Chanza et al.   Journal for ImmunoTherapy of Cancer

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

(2020) J. Haanen et al.   ANNALS OF ONCOLOGY

Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series

(2020) Manuel B. Braga Neto et al.   Clinical Gastroenterology and Hepatology

Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies

(2020) Wenhui Xie et al.   AUTOIMMUNITY REVIEWS

Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

(2020) Yohann Loriot et al.   EUROPEAN JOURNAL OF CANCER

Improving safety of cancer immunotherapy via delivery technology

(2020) Doudou Hu et al.   BIOMATERIALS

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

(2019) Alessio Cortellini et al.   ONCOLOGIST

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

(2019) Yasuto Yoneshima et al.   LUNG CANCER

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors

(2019) Laura C. Kennedy et al.   Journal of the National Comprehensive Cancer Network

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors

(2019) Fausto Petrelli et al.   JOURNAL OF IMMUNOTHERAPY

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

(2019) Alice Tison et al.   Arthritis & Rheumatology

Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

(2019) Aneet Kaur et al.   MEDICINE

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

(2019) Salahaldin A. Tahir et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

(2019) Hamzah Abu-Sbeih et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) J B A G Haanen et al.   ANNALS OF ONCOLOGY

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

(2018) Katharina C. Kähler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis

(2018) Kotaro Matsuda et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

(2018) François-Xavier Danlos et al.   EUROPEAN JOURNAL OF CANCER

PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model

(2018) Maile K. Hollinger et al.   EXPERIMENTAL HEMATOLOGY

Immune checkpoint blockade therapy

(2018) Thomas Wieder et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

(2018) Giulia C. Leonardi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?

(2018) MOISES LABRADOR-HORRILLO et al.   JOURNAL OF RHEUMATOLOGY

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

(2018) Michael F. Gowen et al.   Journal of Translational Medicine

Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience

(2018) Michael D. Richter et al.   Arthritis & Rheumatology

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

(2017) Ralf Gutzmer et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

PD-1 hi CXCR5 − CD4 + T FH Cells Play Defense in Cancer and Offense in Arthritis

(2017) Chunyan Gu-Trantien et al.   TRENDS IN IMMUNOLOGY

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview

(2016) Noel R. Rose   AMERICAN JOURNAL OF EPIDEMIOLOGY

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

(2016) B. Lee et al.   ANNALS OF ONCOLOGY

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

PD-1/PD-L and autoimmunity: A growing relationship

(2016) Mohammad Reza Zamani et al.   CELLULAR IMMUNOLOGY

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity

(2016) Qianxia Zhang et al.   IMMUNITY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

(2016) Katrin Klocke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase

(2016) Rajni Sharma et al.   THYROID

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Prevalence of Autoimmune Disease Among Patients With Lung Cancer

(2016) Saad A. Khan et al.   JAMA Oncology

Systemic lupus erythematosus and malignancies risk

(2015) Song Mao et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

(2014) Bianca van den Berg et al.   Nature Reviews Neurology

Autoimmune encephalitis update

(2014) J. Dalmau et al.   NEURO-ONCOLOGY

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis

(2013) Yan Liang et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo

(2012) J. Gotot et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

(2011) Meleeneh Kazarian et al.   Molecular Cancer

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS